Abstract
Objectives: This study aims to evaluate influence factors for adjuvant chemotherapy regimen choice on the basis of trastuzumab in older human epidermal growth factor receptor 2 (HER2)-positive breast cancer under multi-disciplinary team (MDT) modality. Materials and Methods: HER2-positive breast cancer patients aged ≥ 60 years who received breast cancer surgery between April 2013 and December 2017 in Shanghai Ruijin Hospital were retrospectively enrolled. Clinical and pathological features, MDT recommendations, administration of adjuvant treatment, cardiotoxicity, and disease outcome information were reviewed and analyzed. Results: A total of 222 older HER2-positive breast cancer patients were included and recommended to receive adjuvant chemotherapy plus trastuzumab therapy. Paclitaxel plus trastuzumab (PH, 41/222, 18.5%), docetaxel plus carboplatin and trastuzumab (TCH, 62/222, 27.9%), and antharcyclines plus cyclophosphamide followed by taxanes and trastuzumab (AC-TH, 119/222, 53.6%) were the three main regimens. Patients with T1a-b (P<0.001),<0.001),<0.001),<0.001)<0.001)
PMID: 32201530 [PubMed]
11:30
Photo
Not included, change data exporting settings to download.
256×256, 6.0 KB
11:30
In reply to this message
pubmed: ctoall&ca or conall
TRIB3 promotes lung cancer progression by activating β-catenin signaling.
//www.ncbi.nlm.nih.gov/corehtml/query/egifs/https:--linkinghub.elsevier.com-ihub-images-PubMedLink.gif Related Articles
TRIB3 promotes lung cancer progression by activating β-catenin signaling.
Eur J Pharmacol. 2019 Nov 15;863:172697
Authors: Zhang X, Zhong N, Li X, Chen MB
No comments:
Post a Comment